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The major human soil-transmitted helminths (STH), Ascaris lumbricoides, hookworms (Necator americanus
and Ancylostoma duodenale) and Trichuris trichiura have a marked impact on human health in many parts
of the world. Current efforts to control these parasites rely predominantly on periodic mass administra-
tion of anthelmintic drugs to school age children and other at-risk groups. After many years of use of
these same drugs for controlling roundworms in livestock, high levels of resistance have developed,
threatening the sustainability of these livestock industries in some locations. Hence, the question arises
as to whether this is likely to also occur in the human STH, thereby threatening our ability to control
these parasites. This is particularly important because of the recent increase in mass control programmes,
relying almost exclusively on benzimidazole anthelmintics. It will be important to ensure that resistance
is detected as it emerges in order to allow the implementation of mitigation strategies, such as use of
drug combinations, to ensure that the effectiveness of the few existing anthelmintic drugs is preserved.
In this review we address these issues by ﬁrstly examining the efﬁcacy of anthelmintics against the
human STH, and assessing whether there are any indications to date that resistance has emerged. We
then consider the factors that inﬂuence the effect of current drug-use patterns in selecting for resistant
parasite populations. We describe the tools currently available for resistance monitoring (ﬁeld-based
coprological methods), and those under development (in vitro bioassays and molecular tests), and high-
light confounding factors that need to be taken into account when interpreting such resistance-monitor-
ing data. We then highlight means to ensure that the currently available tools are used correctly,
particularly with regard to study design, and we set appropriate drug-efﬁcacy thresholds. Finally, we
make recommendations for monitoring drug efﬁcacy in the ﬁeld, as components of control programmes,
in order to maximise the ability to detect drug resistance, and if it arises to change control strategy and
prevent the spread of resistance.
 2011 Australian Society for Parasitology Inc. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction/background millionhave signiﬁcantmorbidity attributable to their infection, theThe threemajor humanmajor soil-transmitted helminths (STH),
Ascaris lumbricoides (roundworm), Necator americanus/Ancylostoma
duodenale (the hookworms) and Trichuris trichiura (whipworm)
are amongst themost prevalent parasitesworldwide. It is estimated
that there are more than one billion cases worldwide, of which 450Inc. Published by Elsevier Ltd.
, Faculty of Veterinary Med-
Immunology, Laboratory of
gium. Tel.: +32 9 264 74 90;
cruysse).
Opmajority of whom are children. An additional 44 million infected
pregnant women suffer signiﬁcant morbidity with hookworm-
associated anaemia likely contributing to maternal mortality. It
has been estimated that approximately 135,000 deaths occur each
year due to STH infections (Awasthi and Bundy, 2007), mainly due
to infections with the hookworms through anaemia, the round-
wormA. lumbricoides through intestinal or biliary obstruction (Wani
et al., 2010) and the whipworm T. trichiura through anaemia and
chronic dysentery (Stephenson et al., 2000). Whenmeasured in dis-
ability-adjusted life years (DALYs) lost, that is the number of healthy
years lost to premature death or disability, STH infections are as
important as malaria or tuberculosis (Brooker, 2010).en access under CC BY-NC-ND license.
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is the periodic administration of oneof the four anthelmintics recom-
mended by the World Health Organization (WHO): mebendazole
(MEB), albendazole (ALB), levamisole (LEV) or pyrantel (PYR). Of
these, benzimidazoles (BZ) –MEB and ALB – are themost frequently
used anthelmintics for treatment of STH infections. The costs esti-
mated for drug administration are US$ 0.012–0.91 per subject
(Brooker et al., 2008; Montresor et al., 2010). While ivermectin
(IVM) is not recommended for the treatment of human STH, except
for strongyloidiasis, it has good activity against ascariasis, butmuch
less against hookworms and trichuriasis than the four drugs listed
above (Richards et al., 1995). However, in the new setting where
so-called ‘‘preventive chemotherapy’’ is advocated (World Health
Organization, 2006), IVM merits consideration, as it is the drug of
choice in mass drug administration programmes for controlling
onchocerciasis and as a component of combination treatment for
lymphatic ﬁlariasis. In addition, co-administration of IVM signiﬁ-
cantly improves the activity of ALB against T. trichiura (Ismail and
Jayakody, 1999; Belizario et al., 2003). Therefore, in these settings
IVM will have collateral beneﬁcial effects for some but not all STH
co-infections.
Given the paucity of suitable alternative anthelmintics it is
imperative thatmonitoring programmes are introduced, both to as-
sess progress, and to detect any changes in therapeutic efﬁcacy that
may arise from the selection of worms carrying mutations confer-
ring drug resistance (Albonico et al., 2004a). The scale up of chemo-
therapy programmes currently underway in various parts of Africa,
Asia and South America, particularly targeting school children, is
likely to exert increasing drug pressure on parasite populations. This
has the potential to select for parasite genotypes that can resist
anthelmintics. More than 314 million children were treated for
soil-transmitted helminthiases in 2009 (205 million were treated
in 2008). Although the number of children treated periodically in-
creasedbyone third in2009, 31%coverage is still far belowtheglobal
targetof75%setby theWHOfor2010.Global coverage isnowsimilar
for preschool-aged children (approximately 34%) and for school-
aged children (approximately 30%) (World Health Organization,
2011).
In this reviewwe discuss the problems associated withmonitor-
ing the efﬁcacy of anthelmintics, in order to answer the question as
to whether anthelmintic resistance (AR) is a concern for the control
of human STH, requiring urgent remedial action. Firstly, we review
the studies describing the efﬁcacy of anthelmintics and the prob-
lems relating to the indicators of efﬁcacy. Secondly, we discuss
the different potential confounding factors that may affect the
assessment of efﬁcacy of anthelmintics and that should be taken ac-
count of, or even excluded, before assuming AR in a particular set-
ting. Thirdly, we consider whether the limited number of studies on
reduced efﬁcacy in hookworms represent genuine cases of AR,
based on the selection of resistance alleles in the parasites, or
merely reduced efﬁcacy due to the impact of confounding factors.
Fourthly, factors contributing to AR are reviewed, and ﬁfthly recent
advances in understanding the molecular basis of AR in worms of
livestock are discussed, since these are likely to be highly relevant
for human helminths. Sixthly, the in vivo and in vitro diagnostic
methods for monitoring the emergence of AR are presented. Finally,
the basis for the currently recommended guidelines for monitoring
drug efﬁcacy (World Health Organization, 1999) is discussed and
recommendations for future monitoring are presented.2. Expected efﬁcacies of anthelmintics
The two indicators that are used to determine the efﬁcacy of an
anthelmintic in human medicine, are the cure rate (CR) and the egg
reduction rate (ERR) (Box 1). Although there are signiﬁcantnumbers of studies investigating the CRs and ERRs of anthelmintics
against human STH, many of these cannot be directly compared
because, as pointed out in the systematic review and meta-analysis
of Keiser and Utzinger (2008), many of these studies are con-
founded by methodological considerations e.g. different diagnostic
methods, treatment regimens, drug dose regimens, geographical
location. This review further highlighted the paucity of high quality
studies that are crucial for guiding clinical decisions about which
anthelmintic drug to use in a particular epidemiological setting.
It is important at the outset to recognize that none of the single
dose anthelmintic regimens are recognized as curative therapy
for an individual patient, with current clinical recommendations
advocating multiple doses over one to three days.
Bennett and Guyatt (2000) reported drug efﬁcacy data as CR
and ERR for 400 mg single-dose ALB, 500 mg single-dose MEB
and multiple-dose MEB (100 mg twice daily for three days) in
treating A. lumbricoides, hookworm and T. trichiura infection. They
concluded that marked variation is mainly observed when the CR is
the analysed endpoint. Their major concern in the control of STH
infections was the moderate and low efﬁcacy of single dose MEB
for hookworm and T. trichiura infections, suggesting that such dose
regimens may be sub-optimal. Assuming that the drugs used are of
high quality, any change in the efﬁcacy of BZ for A. lumbricoides
infection would be clearly apparent because expected efﬁcacy lev-
els are so high. In contrast monitoring changes in drug efﬁcacy
against hookworms and T. trichiura is more unreliable because efﬁ-
cacy levels are relatively low and variable.
In their systematic review and meta-analysis of the efﬁcacy of
single-dose oral ALB, MEB, LEV, and PYR pamoate against STH
infections Keiser and Utzinger (2008) could only use CR as the pri-
mary outcome measure, as there were insufﬁcient valid studies, in
the public domain, reporting the ERR. Single-dose oral ALB, MEB,
and PYR pamoate in A. lumbricoides infection resulted in CR of
88%, 95% and 88%, respectively. The efﬁcacy of single-dose oral
ALB, MEB, and PYR pamoate against hookworm infections was
72%, 15% and 31%, respectively. The CRs for infection with T. trich-
iura following treatment with single-dose oral ALB and MEB were
28% and 36%, respectively. No pooled relative risks could be calcu-
lated for PYR pamoate against T. trichiura and LEV for any of the
parasites investigated.
Recently, Vercruysse et al. (2011) evaluated the efﬁcacy of single
dose 400 mg ALB against STH in children in 7 trials located in coun-
tries across Africa, Asia and South-America, using a standardized
protocol. Overall, the highest CRs were observed for A. lumbricoides
(98%) followed by hookworms (88%) and T. trichiura (47%). The var-
iability in the CR for the three parasites could be largely explained
by country (trial), age or the pre-intervention (pre-treatment) fae-
cal egg counts (FEC). The latter is probably the most important fac-
tor as indeed had a considerable effect on the CR of all three STH
infections. This ﬁnding highlights the proposition that the CR
should not be used as an indicator for drug efﬁcacy, as it is sensitive
to variation in the intensity of infection before treatment (see also
Montresor, 2011). Hence, comparisons between populations
(countries, villages, schools, etc.) differing in pre-intervention FEC
are bound to provide different conclusions about drug efﬁcacy. Ther-
apeutic efﬁcacy, as reported by the ERR, was very high for A. lumbric-
oides (99%) and hookworms (95%), but signiﬁcantly lower for
T. trichiura (51%). In addition, there was considerable variation in
ERR for T. trichiura across the different study sites, which could be
largely explained by the mean baseline FEC (Levecke et al., in press).3. Confounding factors affecting anthelmintic efﬁcacy
It is very important to make a distinction between ‘‘reduced
efﬁcacy’’ and ‘‘anthelmintic resistance’’, though in practice it is
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fect the efﬁcacy of an anthelmintic, and should ﬁrst be excluded
before AR can be assumed. Such issues have been extensively
investigated in veterinary intestinal nematode infections, but less
so among species infecting humans.
An important host-related factor is the signiﬁcant variation in
the pharmacokinetics of anthelmintics. A greater understanding
of the pharmacokinetics of anthelmintic drugs such as the BZs in
livestock in the last few years has contributed signiﬁcantly to
improving parasite control in livestock (Ali and Hennessy, 1995).
In contrast there is a paucity of pharmacokinetic and -dynamic
data for anthelmintics in humans (Geary et al., 2010). Since the
broad-spectrum anthelmintic activity of BZ compounds relies on
the extended presence of effective drug concentrations at the loca-
tion of the parasite in its precise niche in the host (Lacey, 1990), it
implies that in humans increased drug concentration at this site
and extending the exposure period of the parasite to the drug
should result in enhanced clinical efﬁcacy (Prichard et al., 1978;
Ali and Hennessy, 1995). If so, manipulation of the formulation
and dose regimen may result in an improved pharmacokinetic pro-
ﬁle, thereby improving drug efﬁcacy. For example, reduction of
feed intake resulted in increased plasma availability of ALB in ani-
mals (Hennessy et al., 1995; Lifschitz et al., 1997). However, in hu-
mans the opposite effect was observed, with a ﬁve-fold increase in
absorption of ALB if administered with a fatty meal (Lange et al.,
1988). In this respect it is important to recognize that there is an
incomplete understanding of the clinical pharamacology of these
drugs in humans. It is often assumed that it is the intraluminal
drug concentration that is primarily responsible for exposing the
parasite to the drug. However, many of these drugs are absorbed
and metabolized in a variable fashion, and drug metabolites may
or may not be active against the parasite. Furthermore, the parasite
may be exposed to the drug while feeding on blood or tissue ﬂuid
or by drug recirculating through the enterohepatic circulation.
Without a comprehensive understanding of the interactions be-
tween host, drug and parasites, optimization of drug formulation
and dose regimens may be difﬁcult. Other confounding host factors
include variations in intestinal transit time, (which is accelerated
by diarrhoea), and diet which alters the rate of intestinal transit,
thereby reducing the duration of exposure of parasites to anthel-
mintic, and thus reducing efﬁcacy (Sanchez et al., 2006).
Pharmacogenetic variation in drug handling, age- related
changes in drug distribution, drug interactions due to concomitant
therapy (anti-inﬂammatorydrugs or antibiotics) and co-morbidities
(e.g. gastrointestinal diseases, malnutrition and immunodeﬁciency)
may also affect anthelmintic efﬁcacy. In addition, many drugs
require a competent immune system to achieve optimal efﬁcacy.
Some food types and drugs such as grapefruit and the antacid
cimetidine have an effect on cytochrome P450-mediated drug
handling at the intestinal luminal interface thereby modifying ALB
pharmacokinetics (Nagy et al., 2002).
Parasite-related confounding factors include infection intensity
and worm fecundity. High infection intensity (parasite burden)
may interfere with the pharmacokinetics (=reduced bioavailability)
of an anthelmintic. Individual studies that have segregated the drug
efﬁcacy data, by class of intensity, have demonstrated a reduction
in CR and ERR at high intensities of T. trichiura and hookworm infec-
tions (Bennett and Guyatt, 2000). Combining the ERR results of ﬁve
recently conducted efﬁcacy trials revealed a similar trend, yet only
for T. trichiura (Vercruysse et al., 2011; Levecke et al., in press).
Across these trials, the ERR for T. trichiura dropped linearly as a
function of the mean baseline FEC. From this analysis, it was de-
duced that a single dose of ALB, provided satisfactory efﬁcacy
(ERR >90%) results for T. trichiura only when the mean baseline
FEC were <275 EPG. Secondly, this study highlighted the concern
that the current thresholds used for assessing anthelmintic efﬁcacyin T. trichiura (ERR <50%) may lead to incorrect conclusions about
anthelmintic resistance, particularly when the mean baseline FECs
are high (>800 EPG). It is important to state that, in contrast to the
meta-analysis of Bennett and Guyatt (2000), these trials were stan-
dardized in terms of drug (single dose ALB 400 mg from GSK), fol-
low-up (14 days) and diagnosis (McMaster egg counting method).
Anthelmintics may also have a paradoxical effect on worm
fecundity by changing infection intensity thereby confounding
estimates of ERR. In a study by Kopp et al. (2008) a signiﬁcant in-
crease in egg production by hookworms was observed following
drug treatment in dogs. The authors suggested that this was most
likely a consequence of the relaxation of density dependent con-
straints on the egg output of the adult worms that survived the
drug treatment, as female fecundity is inversely related to adult
worm density. It is most likely that this phenomenon also applies
widely to the human STH (Kotze and Kopp, 2008), and if so, drug
efﬁcacy changes based on ERR may be underestimated against a
background of dynamic female worm reproductive biology.
Finally, additional confounding factors include those related to
anthelmintic formulations and especially the quality of the drug.
Differences between batches in the quantity of the active ingredi-
ent in a drug formulation, its bioavailability, and/or degradation
during storage/transport may result in variable efﬁcacy. For lumi-
nal-acting anthelmintics, particle size is very important (ﬁne par-
ticular size is far superior to coarse); this is likely to be affected
by passage along the intestine (Kelly et al., 1975; Wesche and
Barnish, 1994). In addition to the quality and concentration of ac-
tive ingredients, anthelmintics must meet the International
Pharmacopoeia standard of dissolution and disintegration times
that may affect drug efﬁcacy (Albonico et al., 2007). Although little
is known about the quality of anthelmintics sold for human use,
several publications have reported variability in the quality of gen-
eric anthelmintics used in veterinary medicine. The concentrations
of nine anthelmintic products (LEV and MEB) purchased in phar-
macies and from agricultural merchants in Kenya varied from 0%
to 118% of their claimed composition (Monteiro et al., 1998). Efﬁ-
cacy studies of seven brands of ALB against gastrointestinal nema-
todes in sheep in Ethiopia showed that the efﬁcacy of only ﬁve of
the seven brands was satisfactory (Kumsa et al., 2010). Lifschitz
et al. (2004) compared the plasma concentration proﬁles of four
randomly chosen generic IVM formulations and observed major
differences in drug kinetic behaviour. Therefore it appears that
quality control in generic veterinary formulations of anthelmintics
is often inadequate (van Wyk et al., 1997). As underdosing selects
for the development of AR in target parasites this may represent a
major concern in human medicine as well.4. Evidence of reduced efﬁcacy
The possible development of AR to currently available anthel-
mintics is a subject of considerable interest. In livestock, resistance
to all three of the major anthelmintic classes used (BZ, imidothiaz-
oles-tetrahydropyrimidines and macrocyclic lactones (ML)) is
widespread, and has been extensively studied (Wolstenholme
et al., 2004; Sutherland and Leathwick, 2011). While it is possible
that a similar situation to that observed among veterinary STH
might develop in human STH in the future and putative resistance
alleles have been found in human STH, currently there are no con-
clusive data, possibly due to the lack of tools and investigation,
demonstrating that putative resistance alleles have increased in
frequency in human STH following anthelmintic treatment, and
none that these alleles have spread in the parasite populations.
Geerts and Gryseels (2001) reviewed the reports on drug resis-
tance in human helminths and concluded that two studies (De
Clercq et al., 1997; Reynoldson et al., 1997) provideddata suggestive
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providing conclusive evidence. De Clercq et al. (1997) observed no
reduction in the number ofNecator eggs and a CR of only 22.9% after
treatment with a single dose of MEB 500 mg. A standard egg hatch
assay indicated that the Mali strain of N. americanus was almost
twice as resistant to BZ as the laboratory reference strain (ED50 of
0.117 compared to 0.069). However, the signiﬁcance of this differ-
ence in ED50 is difﬁcult to assess given the very different genetic
backgrounds of the isolates. A similar study in the same region
(Sacko et al., 1999) with a single dose of ALB 400 mg resulted in a
CR of 51.4% and a ERR of 77.6%, both signiﬁcantly higher than re-
ported earlier by De Clercq et al. (1997). Thus the studies fell short
of providing conclusive evidence of AR against BZ in Mali.
The most likely reason for the failure of PYR (10 mg/kg) in the
treatment of Ancylostoma (ERR of 46% and CR of 13%) according
to Reynoldson et al. (1997) was the development of resistance as
a consequence of the drug’s frequent use in the community over
many years. However, the low number of patients (n = 15) and
the high pre-treatment egg counts (mean baseline FEC = 869
EPG) may have affected the estimate of efﬁcacy.
In Vietnam, a single dose MEB was found to have disappointing
efﬁcacy against hookworm infections (reduction of mean EPG rel-
ative to placebo was only 31%) (Flohr et al., 2007). However, AR
seemed unlikely as repeated dosing with MEB during 3 consecutive
days in a second study resulted in a reduction of the mean EPG rel-
ative to placebo by 63%. It should also be noted that the second
study was conducted among adults (in contrast to children in the
ﬁrst study) with higher pre-treatment burdens compared to the
ﬁrst study (2210 EPG vs. 263 EPG), potentially confounding com-
parison and/or leading to bias.
On Pemba Island, Zanzibar, the efﬁcacy of MEB against hook-
worms in school children appeared to have fallen over a period
of 5 years, during which time the children were regularly treated
with MEB (ERR fell from 82.4% to 52.1%). This suggested the possi-
bility of emergence of MEB-resistant hookworms on Pemba Island
(Albonico et al., 2003). In support, an in vitro study using an egg
hatch assay showed a lower thiabendazole ED50 compared to the
veterinary resistance-threshold for Haemonchus contortus. How-
ever, this comparison between livestock and human worm species
is far from ideal, and more studies are required before a speciﬁc
efﬁcacy/resistance threshold for human hookworms can be
unequivocally agreed (Albonico et al., 2005) (see Section 7.2).
Molecular studies were conducted on the hookworm population
of Pemba Island but no evidence was found for the b-tubulin muta-
tion at amino acid residue 200 (Phe/Tyr) (Albonico et al., 2004b;
Schwenkenbecher et al., 2007).
No studies have been published on AR in A. lumbricoides. The
presence of the Phe200Tyr SNP (single nucleotide polymorphism)
in b-tubulin was detected in low frequency in T. trichiura from
non-treated people from Kenya and at high frequency in T. trichiura
from treated people from Panama (Diawara et al., 2009). However,
these SNP frequencies could not be linked to AR as sample sizes
were small, anthelmintic efﬁcacy was not assessed, and drug trea-
ted and non-treated samples were from different locations.
To date all reports indicating disappointing efﬁcacy among the
BZs have concerned MEB, and even in studies where MEB had
low efﬁcacy (Sacko et al., 1999), ALB was used as the positive con-
trol and showed extremely high efﬁcacy against hookworms (See
also Vercruysse et al., 2011). It is therefore of some concern that
a recent report from Ghana has indicated a high failure rate for
ALB in the treatment of hookworm infections (Humphries et al.,
2011). Although the ERR was 82% following treatment of 102 in-
fected subjects, the CR was only 61%. Even more worrying was
the observation that within the group that did not respond to
ALB treatment, FECs did not drop after treatment. While this study
was not primarily designed as an anthelmintic trial, the work wasthoroughly conducted and analyzed, and the ALB tablets were con-
ﬁrmed as actually having been swallowed by all study subjects.
To conclude, the number of studies assessing AR in human STH
is currently very limited, and the studies to date suffer from a num-
ber of serious ﬂaws: almost none deal with potential confounding
factors (e.g. quality of the drugs), many are based on only low
numbers of subjects and are signiﬁcantly underpowered, the ab-
sence of standardised protocols and diagnostic techniques, and a
lack of any agreed thresholds for deﬁning AR. Therefore, it remains
uncertain still whether the reports on reduced efﬁcacy in hook-
worms represent genuine cases of AR, based on the selection of
resistance alleles in the parasites, or rather, whether they simply
reﬂect reduced efﬁcacy.5. Factors contributing to the development of anthelmintic
resistance
Four factors have been identiﬁed as contributing to the develop-
ment of AR: (1) initial resistance allele frequency, (2) treatment
frequency, (3) refugia and (4) possibly underdosing.
5.1. Initial resistance allele frequency
At this stage, there is almost no information on the frequency of
putative resistance alleles, based on veterinary parasites, in human
STH, although the tools are now available for assessing this for BZ
in treatment naive and treated populations infected with STH.
5.2. Treatment frequency
This is an important determinant of the speed of selection of
AR: the greater the drug pressure (related to treatment frequency,
relative ﬁtness of resistant compared with susceptible worms, dose
regimens, survival of free-living stages, refugia and other factors),
the faster the selection of resistant nematode strains. Treatment
frequencies of 5 or more times a year (up to 10 treatments/year)
are not uncommon in livestock (Dorny et al., 1994). In humans,
the frequency of treatments is usually limited to 1–3 per year for
A. lumbricoides/hookworms/T. trichiura (Warren et al., 1993;
Renganathan et al., 1995). However, even at these lower treatment
frequencies, selection of AR has been repeatedly reported in sheep
and goat nematodes (Coles, 1995; Boudsocq et al., 1999). This is
especially the case when the same drug has been used over pro-
longed periods, as is the case with BZ in the control of human
STH, and this combined with lower treatment frequencies might
be enough to select for resistance. This has been clearly shown in
nematodes of livestock, where farmers tend to use a single drug
until it fails (Reinemeyer et al., 1992).
5.3. Refugia
The phenomenon of refugia, i.e. the proportion of the parasite
population that is not exposed to drugs and thus escapes selection
for resistance, is a very important factor in the selection pressure
for development of resistance, and one whose impact on the devel-
opment of AR is too often overlooked (van Wyk, 2001). The size of
refugia will be mainly determined by (1) the fraction of the popu-
lation treated (i.e. mass treatments versus selective or targeted
selective treatments) and (2) the proportion of the worm popula-
tion present in the environment where it is not subject to drug ac-
tion (e.g. in the soil). This is inﬂuenced in turn by a range of factors
including climate, resilience of the transmission stages in the face
of environmental stressors and longevity of the free-living stages.
For most of the STH of human importance there is still a poor
understanding of the exact role of these important parameters,
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mathematical models. Mathematical modelling in veterinary para-
sitology has shown that it is possible to delay the development of
AR by not treating part of the herd or ﬂock. Whether this is ethi-
cally acceptable in human chemotherapy programmes is a highly
debatable/controversial topic, and in the current climate is unlikely
to be given approval by ethical review committees.
Dobson et al. (2011) showed that leaving some sheep untreated
worked best in situations where animals were already grazing or
were moved onto pastures with low populations of infective
larvae. In those cases, AR was delayed and nematode control was
maintained when 1–4% of adult stock remained untreated.
In control programmes of human STH, treatment is often direc-
ted at speciﬁc target groups typically school-aged children (they
often remain in school for 5 years and therefore most children
can be guaranteed to have received a set number of treatments)
and other population groups at greatest risk of morbidity. This
effectively provides refugia, especially for hookworm as adults tend
to harbour greater worm burdens than children. Thus targeting
school children likely reduces the selection pressure on hook-
worms. This effect is further magniﬁed because coverage and com-
pliance is often less than 80% (Chitsulo et al., 2000). On the other
hand mass treatment with ALB is now a standard component of
the The Global Programme to Eliminate Lymphatic Filariasis
(GPELF) and ALB is being distributed to all communities as part
of the Schistosomiasis Control Initiative (SCI) activities.
The size of refugia is also largely determined by factors such as
the timing of the treatment and the climatic conditions immedi-
ately prior to treatment as both will inﬂuence selection pressure
on the parasites. Treatment of humans under very dry climatic
conditions may strongly select for an increase in the proportion
of resistant worms because the climatic conditions will kill previ-
ously deposited eggs and larvae on the soil surface. However, in
wetter environments, pre-parasitic stages of susceptible worms
might survive in the environment and dilute the resistant genes
in subsequent generations. However, the relevance of the timing
of treatment on the refugia for the human STH is yet to be thor-
oughly studied. Treating at times of the year when a high propor-
tion of parasites are in refugia in the environment, should delay the
spread of resistance. However, the purposeful timing of MDA pro-
grammes may present logistic problems and be less effective in
controlling the overall community worm burden. Villagers are usu-
ally more easily accessible in the dry season, so that entire commu-
nities can be treated simultaneously, whereas in the wet season
people may leave villages early to work on their agricultural plots
and thus be more difﬁcult to reach for treatment, so a compromise
has to be achieved.5.4. Underdosing
Underdosing may constitute another risk factor for the develop-
ment of AR. As was shown in the models developed by Smith et al.
(1999), the impact depends on the initial (before exposure to a gi-
ven anthelmintic) and the resultant (after treatment) frequency of
resistance alleles in the helminth population. Depending on their
ability to kill all or part of the susceptible homozygote, heterozy-
gote and/or homozygote resistant helminths, and on the initial fre-
quency of resistant alleles, speciﬁc dose regimens may select for AR
in different ways. Assuming that resistance is determined by a sin-
gle major gene comprising two alleles at a single autosomal locus
and low initial frequency of the allele for resistance, the most dan-
gerous dose is the one that kills all susceptible homozygotes but
none of the heterozygous or homozygous resistant genotypes. In
contrast, when the initial frequency of the allele for resistance is
high, the dose that most strongly promotes resistance is the onethat kills all susceptible homozygotes and all heterozygotes, but
none of the resistant homozygotes (Smith et al., 1999).
Sub-optimal regimens are the rule in human treatment: anthel-
mintics are administered in single doses that never achieve 100%
efﬁcacy, a practice that is widely advocated and implemented in
public health helminth control programmes. While the operational
objectives are laudable: to ensure compliance of the target popula-
tion where the objective is only morbidity control (Warren et al.,
1993), this may have unwanted consequences when applied
widely and over a signiﬁcant period. Taking into account the lim-
ited efﬁcacy of single dose anthelmintic treatments, the current ap-
proach might select for resistance under certain conditions. The
efﬁcacy of most anthelmintics at the dose rates used, is only mod-
erate for the human STH (compared to veterinary STH with ERR of
>98%). It is apparent that the currently recommended dose regi-
mens are underdosing parasites in humans. However, data beyond
the scope of this paper indicate that increasing the size of the sin-
gle dose of BZ will not always result in increased efﬁcacy because
the nature of their antiparasitic action depends on prolongation of
contact time (Vercruysse, 2005). While repeated dosing is more
effective, this approach is difﬁcult to implement in public health
programmes, because coverage falls with time when it is necessary
to ask subjects to return for repeated treatment or to take daily
unsupervised therapy.
Thus currently recommended regimens could constitute a sig-
niﬁcant contributing factor to the development of AR in STH. On
the other hand, suboptimal dose regimens may exert less selection
pressure for AR development than would dose regimens that ini-
tially produced virtually 100% efﬁcacy. These alternative possibili-
ties need to be investigated experimentally as well as through
mathematical modelling. The subject of anthelmintic dosing and
the pharmacodynamics and pharmacokinetics of anthelmintics in
humans have been addressed in a recent review (Geary et al.,
2010).6. Advances on the molecular basis of AR
Knowledge of the genetics of AR in helminths is still incomplete.
Nevertheless a number of important principles derived from the
study of livestock helminths are likely to be relevant for human
helminths. The rate at which AR develops and spreads in helminth
populations will depend on a range of factors, including population
structure, gene migration and the prevalence of resistance alleles
in the initial untreated population. To date very little information
is known about population structure in human STH, or about gene
migration, although the latter could be expected to be high in hu-
man STH given the levels of human migration. Studies in veteri-
nary nematodes (e.g. Skuce et al., 2010) suggest that resistance
mutations may arise independently in different populations and
then be transported by host migration. The prevalence of resis-
tance alleles is usually considered to be low. However, in untreated
H. contortus populations, the initial prevalence of RFLP polymor-
phisms associated with resistance to BZ at the isotype 1 and 2 b-
tubulin loci were 46% and 12%, respectively; surprisingly high
ﬁgures (Beech et al., 1994). Similarly high (10–20%) prevalence of
genetic polymorphisms associated with IVM resistance were re-
ported in unexposed H. contortus (Anderson et al., 1998). However,
these were not actual alleles, but restriction length polymorphisms
(RFLP), which may have contained more than a single allele, so that
the prevalence of a resistance causing SNP may have been lower
than this ﬁgure.
The best understood type of AR is BZ resistance. In veterinary
nematodes changes at Phe200Tyr or Phe167Tyr (both TTC–TAC),
or rarely Glu198Ala (GAA–GCA) in b-tubulin confer BZ-resistance
(Kwa et al., 1994; Ghisi et al., 2007; Mottier and Prichard, 2008).
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of the 200Tyr codon in b-tubulin, in ﬁve different populations
(each with between 38 and 101 individual parasites) of BZ suscep-
tible Teladorsagia circumcincta, and found for the total population
of 281 diploid organisms genotyped, that the overall prevalence
of alleles containing the 200Tyr codon was 2.7%. However, the
range of prevalence of the resistance-associated codon 200 was be-
tween 0% and 12.0% in the ﬁve different susceptible populations.
The rapid development of resistance to IVM and BZ in helminths
of livestock may be explained, in part, by an initial high prevalence
of resistance alleles in some populations of nematodes. Data on the
prevalence of putative AR alleles in STH of humans are only now
being collected (see e.g. Schwenkenbecher et al., 2007; Diawara
et al., 2009) and need to be investigated as a priority.
The number of genes involved in resistance and their mode of
inheritance (dominant or recessive) are additional factors with an
important inﬂuence on the rate at which AR spreads. Polymor-
phism in b-tubulin isotype 1 seems to be most important for BZ
resistance in H. contortus (Mottier and Prichard, 2008). Recently,
our understanding of LEV resistance has greatly advanced with
Boulin et al. (2011) reporting that a number of changes in several
genes, which together encode the acetylcholine receptor, result
in loss of the LEV-sensitive acetylcholine receptor and thereby
may cause resistance in veterinary nematodes. These data together
with the ﬁndings of Kopp et al. (2009) suggest that resistance to
the nicotinic drugs is based on changes in the expression of the
subunits that together form the receptor. Although monepantel, a
recently developed veterinary anthelmintic for sheep, has not been
used to date to treat human parasites, resistance can be relatively
easily selected in H. contortus in the laboratory. Under such in vitro
selection pressure a number of possible genetic changes in the Hco-
mptl-1 gene result in the loss of a functional monepantel-sensitive
acetylcholine receptor (Rufener et al., 2009). IVM resistance is
thought to be polygenic, and while it is thought that P-glycopro-
teins are involved in IVM resistance, a detailed understanding of
the genetic basis of resistance is still lacking (Prichard, 2007).
Although there is ongoing debate about the number of genes in-
volved in resistance to these different anthelmintics, of major
importance to human medicine is the observation that, at least
for BZ and ML resistance, reversion to susceptibility is rare once
AR has developed in helminths of livestock, even when other drugs
with completely different mechanisms of action are used for pro-
longed periods. This is an observation of major importance and is
supported by a signiﬁcant body of ﬁeld and experimental data (re-
viewed by Conder and Campbell, 1995).
Although the ﬁndings from veterinary helminths should not be
extrapolated directly to humans, the likelihood that similar phe-
nomena apply in STH of medical importance should not be
overlooked.7. Monitoring the emergence of AR
7.1. Coprological methods
To date, the clearance of eggs from stools (CR) and the egg
reduction rate (ERR), remain the most widely applied metrics for
monitoring drug efﬁcacy. Of these two indicators of drug efﬁcacy,
the CR has been the most frequently reported (Keiser and Utzinger,
2008), yet it is less sensitive to changes in drug efﬁcacy (Box 1).
This is because drugs with an equal CR may nevertheless show sig-
niﬁcant differences in ERR. Although expert consensus holds that
the ERR is the best parasitological measure for future surveillance
of changes in drug efﬁcacy, the level of understanding of the effects
of the factors inherent both in study design (diagnostic method,
sample size and statistical analysis) and host–parasite interactions(level and variation in egg excretion between and within subjects)
is still too poor to support agreement for an acceptable standard-
ized protocol.7.1.1. Diagnostic methods
Currently, three diagnostic methods are used to assess drug efﬁ-
cacy in human trials. These include the WHO recommended and
widely used Kato-Katz thick smear (World Health Organization,
1991, 1999), the more recently developed FLOTAC method
(Cringoli et al., 2010; Knopp et al., 2011) and the much older
McMaster egg counting method (Ministry of Agriculture Fisheries
and Food, 1986; Vercruysse et al., 2011). These three diagnostic
methods differ considerably in terms of their diagnostic perfor-
mance, their sensitivity, accuracy (degree of deviation from ‘true’
FEC or bias) and precision (degree of repeatability of FEC results
performed on the same stool sample) of assessing FEC; and in
terms of their ease of use under ﬁeld conditions (need for ﬁnancial,
human and technical resources). Although justiﬁably considerable
emphasis has been placed in the past on the sensitivity of diagnos-
tic methods and, this is highly relevant for a qualitative indicator,
such as CR, the impact of sensitivity on ERR is likely to be less
important. This became apparent in a recent study; where differ-
ences in sensitivity both between diagnostic methods (Kato-Katz
thick smear and McMaster egg counting technique) and between
laboratories across Africa, Asia and Latin America resulted in less
accurate CR results, but not for ERR (Levecke et al., 2011a). There-
fore, the ERR based on quantitative FEC, because of its greater accu-
racy and precision, is a more reliable method for both diagnosis
and assessment of drug efﬁcacy. Comparative studies of quantita-
tive diagnostic techniques have been conducted in veterinary sci-
ences, and have indicated recently that the FLOTAC method
provides an even more accurate and precise FEC and while the
McMaster method is accurate, it nevertheless lacks precision
(Cringoli et al., 2010, 2011; Rinaldi et al., 2011). These differences
in precision between both methods can be largely explained by
the mass of stool examined, up to 1 g for FLOTAC (1 observed
egg being equivalent to 1 egg per gram stool (EPG)) and only
20 mg for McMaster method (1 egg observed being equivalent to
50 EPG). Similar in-depth studies of the assays deployed in public
health settings are not available, yet a few studies have demon-
strated that the Kato-Katz method results in signiﬁcant higher
FEC than the FLOTAC method (Knopp et al., 2009a,b) and the
McMaster egg counting method (Levecke et al., 2011a), suggesting
it is the least accurate method. Based on the mass of stool exam-
ined in a Kato-Katz thick smear (41.7 mg, and 1 egg observed is
equivalent to 24 EPG), the precision of this method should be lower
than the FLOTAC method. Whether in practice it is more precise
than the McMaster egg counting method, however, still remains
unclear. This is because, despite the use of the standard template,
there is considerable variation in the actual mass of stool examined
in a Kato-Katz thick smear (Engels et al., 1997; Levecke et al.,
2011a), and not unexpectedly this contributes greatly to increasing
the variability in FEC. Of the three diagnostic methods currently
used, it is the authors’ view that the McMaster method is the most
feasible and most adaptable for ﬁeldwork. Its advantage include its
simplicity and the fact that it does not require any apparatus, other
than a microscope and calibrated McMaster slides (vs. FLOTAC
which also requires a centrifuge and a specialized cell) and allows
simultaneous enumeration of the eggs of all STHs (vs. Kato-Katz
thick smear which tends to be unreliable with hookworm eggs).
Based on previous studies assessing the cost of these diagnostic
methods, it is estimated that the average time for preparing, read-
ing and examining one stool sample is 5 min for the McMaster
method, 10 min for the Kato-Katz smear and 15 min for FLOTAC
(Levecke et al., 2009; Speich et al., 2010; Cringoli et al., 2010).
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The required sample size will not only depend on the accuracy
and precision of the diagnostic method (e.g. FLOTAC will require
smaller sample sizes compared to McMaster method), but this will
also be affected by the level and variation in egg excretion between
subjects. In veterinary sciences, there is already empirical evidence
that low FECs may confound interpretation of ERR results, particu-
larly when sample sizes are small or diagnostic methods are not
precise (El-Abdellati et al., 2010; Levecke et al., 2011b), and this
is supported by evidence from statistical modelling (Vidyashankar
et al., 2007). As a consequence, performing an ERR where all three
STHs are being evaluated concurrently in the same population, re-
quires a different study design, especially because of the differ-
ences in fecundity between the helminth species: A.
lumbricoides >> hookworm > T. trichiura (Bethony et al., 2006). In
addition, there is considerable variation in egg excretion between
subjects (Maizels et al., 1993), with the majority of subjects either
excreting no eggs or low numbers of eggs. As a consequence of this,
small sample sizes or less precise diagnostic methods are likely to
impede accurate estimation of ERR.
In a ﬁrst attempt to gain more insights into the ERR, Levecke
et al. (unpublished results) performed a statistical simulation in
which the ERR was carried out under varying conditions of sample
size, precision of diagnostic methods, level and variation of egg
excretion. This analysis suggested that a sample size of between
of 50 and 200 subjects is required for a reliable estimation of
ERR, irrespective of the infection status (negative/positive), More-
over, the results indicated that for these sample sizes, greater pre-
cision of the diagnostic method did not signiﬁcantly improve the
detection of reduced efﬁcacy, highlighting that in practice the fea-
sibility of using a particular method in a given situation in the ﬁeld
is perhaps a more important determinant of the choice of diagnos-
tic method. For smaller sample sizes, variation in egg excretion im-
peded a successful interpretation of the ERR, even when precise
diagnostic methods were applied.
7.1.3. Statistical analysis
Wherever possible, statistical analysis should include assess-
ment of the effect of treatment with age, sex and any other rele-
vant factors, simultaneously in multi-factorial tests. With the
development of fast, powerful and relatively cheap laptop comput-
ers, large and robust statistical programmes, that control for these
confounding variables, and most importantly pre-intervention
intensity can now be used relatively easily in the ﬁeld. However,
it should be noted that statistical tests are best applied to data ac-
crued at the individual subject level (individual-based formulae,
see below), where the value of FEC or change in FEC is the depen-
dent variable. As discussed below, an important recommendation
of this review is that ERR should be calculated at the group level
and the outcomes of these can only be compared to established
and agreed threshold of efﬁcacy (Box 1). Tests based on random-
ised sub-sampling of the data acquired from large trials can be
used to establish 95% conﬁdence limits (bootstrap analysis) and
the degree to which these overlap with agreed threshold for
efﬁcacy.
An often neglected factor that is now known to have a profound
effect on efﬁcacy of treatment is the intensity of infection prior to
treatment. Montresor et al. (1998) recommended the following
ranges of egg counts corresponding to low, moderate and high
intensities of infection for A. lumbricoides (1–4999 EPG,
5000–49,999 EPG and P50,000 EPG), for hookworms (1–1999
EPG, 2000–3999 EPG and P4000 EPG) and for T. trichiura (1–999
EPG, 1000–9999 EPG and P10,000 EPG), respectively, and these
can be included in analyses based on individual-based formulae
(see below) as levels within a factor accounting for pre-interven-
tion FEC. Alternatively for treatment group–based formulae, ERRcan be calculated separately for each class of pre-intervention
intensity. However, it is not always possible to ﬁnd sufﬁcient num-
bers of subjects that ﬁt these different intensity levels, especially
the moderate and high intensity categories.
Important differences in ERR have been observed depending on
the formula used to calculate the reduction in FEC. Individual-
based formulae are likely to be less accurate (underestimation of
the ERR) and less precise (large 95% conﬁdence intervals) com-
pared to group-based formulae (Cabaret and Berrag, 2004; Levecke
et al., 2011b; Vercruysse et al., 2011). In addition to this, Dobson
et al. (2009) also reported that that ERRs calculated using geomet-
ric means are more prone to bias than ERRs calculated using arith-
metic means. Therefore, group-based ERR calculated using
arithmetic means are the best available indicator of drug efﬁcacy,
and should be adopted in future monitoring and evaluation studies
of large-scale anthelmintic treatment programmes, and as indi-
cated above, presented for each pre-intervention intensity cate-
gory separately as well as for the all subjects combined.
7.2. In vitro biological assays
A number of tests are available for the measurement of drug
sensitivity in livestock nematodes using free-living life stages.
These include the egg hatch test (EHT; Dobson et al., 1986; Coles
et al., 2006) larval development assay (LDA; Hubert and Kerboeuf,
1992; Gill et al., 1995), motility and/or migration assays (Gill et al.,
1991; Kotze et al., 2006), and a recently described larval arrested
morphology assay (LAMA; Kopp et al., 2008). The most suitable test
for use with the human STH will depend on several factors, includ-
ing the drug group(s) of most interest, practical factors associated
with the ease of use of the various assays in the ﬁeld, and, most
importantly, which tests are shown to be most effective at indicat-
ing the presence of drug resistance with the human STH. A signif-
icant issue in the potential for application of these tests to human
STH is that, in their current form, they are only applicable to hook-
worms. The assays require either the isolation of eggs or infective
larval stages, and while this is possible with hookworms as their
eggs hatch rapidly after isolation from faeces, it is not relevant
for A. lumbricoides and T. trichiura which develop to the infective
stage within the egg and do not hatch until ingested by the host.
Further work will be required to develop drug sensitivity assays
for these species. One possibility may be to modify the LDA for
these species to examine larval development within the eggshell
(Eriksen, 1990) rather than following hatch as with the current
livestock LDA.
The World Health Organization (1999) has promoted the evalu-
ation and standardization of the EHT in human helminthology, and
the test has been used a number of times to describe BZ sensitivity
in human hookworms (De Clercq et al., 1997; Albonico et al., 2005;
Kotze et al., 2005). These latter two studies showed that the EHT is
a reproducible test under ﬁeld conditions, and that it was effective
in quantifying drug sensitivity in drug-susceptible hookworms.
Kotze et al. (2009) subsequently examined the responses of canine
and human hookworms using a 96-well assay format as a possible
means for standardising the use of EHTs at different ﬁeld sites. The
assay format they described has subsequently been used to effec-
tively deﬁne hookworm BZ sensitivity at ﬁeld sites in Brazil (Kotze
et al., unpublished data) and China (Kotze et al., 2011). This latter
study highlighted logistical difﬁculties that may arise in sample
collection and processing procedures of human faeces compared
to livestock, and a number of measures for the use of EHTs were
recommended for improving study outcomes in future ﬁeld-based
human studies. These measures included the need to monitor the
degree of egg embryonation in egg samples where the local sam-
pling methods required the use of an overnight period for children
to produce a stool, the need to account for the impact of this on
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groups of 5–10 individuals within a study population.
Although, in studies carried out to date using the EHT it has
been possible to deﬁne a measure of BZ sensitivity in the ﬁeld, a
great deal of work remains to be done to validate the test as a resis-
tance diagnostic tool for human hookworms because there are no
known drug resistant isolates available to study correlations be-
tween the results of EHT and drug efﬁcacy data as determined by
FEC reduction. In addition, more studies are needed to further stan-
dardise the technique so that data from different ﬁeld sites, or from
different time points, can be compared with conﬁdence. If the test
proves able to discriminate between susceptible and resistant pop-
ulations, there is a need to deﬁne concentration thresholds that
indicate the presence of resistance. This has been done for the live-
stock species, thereby allowing the adoption of EC50 and EC99 val-
ues as being indicative of resistance (Coles et al., 1992, 2006). More
baseline data from different human hookworm populations, as
well as some assay data using known resistant populations, are re-
quired in order to deﬁne such thresholds. Even though the EHT is
fairly standardised in veterinary medicine, evidence of variability
between laboratories exists, and several factors need to be stand-
ardised/agreed upon in order to minimise variation (von Samson-
Himmelstjerna et al., 2009). Preparation of assay reagents in a
‘quality controlled environment’ by a limited number of laborato-
ries, and their distribution to ﬁeld sites may help overcome some
of these inconsistencies (Kotze et al., 2009).
The LDA has also been used for resistance diagnosis in the live-
stock industries (Hubert and Kerboeuf, 1992; Coles et al., 1992; Gill
et al., 1995). An LDA kit was sold commercially in the 1990s and
early 2000s in Australia as the Drenchrite™ test for detection of
resistance to BZ, nicotinic agonist, and ML drugs in sheep nema-
todes (Lacey et al., 1990). Although it was effective in detecting
resistance to the ﬁrst two of these drug groups in all the important
nematode species, and detecting ML resistance in H. contortus, its
use declined greatly as it was not effective in identifying ML-resis-
tant Ostertagia spp. (Lloyd, 1998; Palmer et al., 1998) However, gi-
ven its usefulness with the livestock species and the two drug
groups of most importance for human hookworms, that is, the BZ
and nicotinic agonists, there is potential in its use in the human
ﬁeld. An advantage of using an LDA would be that BZ and nicotinic
agonists could be examined in a single assay, whereas the EHT is
only applicable to BZ. Although IVM sensitivity could also be mea-
sured simultaneously, as mentioned above, the LDA was unable to
detect ML resistance in Ostertagia spp.
Recently, a motility assay and a novel assay (LAMA) were devel-
oped to measure pyrantel sensitivity in canine hookworms (Kopp
et al., 2008). These assays were subsequently examined with hu-
man and rodent-adapted human hookworms, allowing for a stan-
dard assay format of drug concentrations to be described (Kotze
et al., 2009). However, as described above for the EHT and LDA,
the ability of the assays to diagnose PYR resistance with human
hookworms will remain unknown until they can be tested against
isolates of human hookworm known to be resistant to the nicotinic
agonist drugs. An important note here is that unlike the EHT, these
motility/LAMA tests have been shown to distinguish between sus-
ceptible and resistant canine hookworms due to the availability of
such isolates with this species (Kopp et al., 2008). In contrast, no
BZ-resistant canine hookworm isolates have been reported in the
literature, and these would be useful for providing a degree of val-
idation for the EHT. An advantage of these motility/LAMA tests is
that the collection of the biological material, namely infective stage
larvae after migration from faecal cultures, is much less laborious
than the puriﬁcation of eggs from faeces as is required for the
EHT and LDA. It is apparent that development of a high throughput,
robust quantitative assay for determining drug response would
represent a major advance. In this respect, a number of recentreports of prototype assays have been published (Smout et al.,
2010; Chen et al., 2011). Whether these assay platforms are suit-
able for ﬁeld deployment remains to be established.
It is clear that further work is required to develop and validate
the use of in vitro biological assays for diagnosis of resistance with
human STH. These assays represent an intermediate stage in sensi-
tivity between the ERR and molecular tests. However, they are
more immediately applicable than the molecular tests which, as
described above, will take some time before they can relate allele
frequencies to drug efﬁcacy. The in vitro diagnostic tests therefore
represent a means for detecting the emergence of resistance in
hookworms in the crucial period before molecular tests become
available. Assessment of BZ sensitivity with hookworms using
the EHT is the most advanced test and could be used more widely
in the ﬁeld now. Although questions remain as to its ability to diag-
nose resistance in human hookworms, its utility with livestock
nematodes (Coles et al., 1992, 2006) should generate conﬁdence
in its usefulness with the human hookworm species. The priorities
should be further standardisation of methods, the collection of
baseline data, and the use of the assays with known, or suspected,
resistant isolates when these become available through either
identiﬁcation in current efﬁcacy trials (for example, Vercruysse
et al., 2011), or through laboratory-based selection. The second
area of interest should be the examination of the assays suitable
for the nicotinic agonist drug group. Of these, the combination of
a motility and arrested morphology assay may offer the most
promise (Kopp et al., 2008; Kotze et al., 2009). As mentioned above,
a further priority should be the development of suitable in vitro
biological tests for T. trichiura and A. lumbricoides.8. Recommendations for monitoring drug efﬁcacy
The Guidelines on how to monitor drug efﬁcacy in public health
were published by the WHO in the late 1990s (World Health
Organization, 1999). These provided recommendations on sample
size (200 infected subjects equally representing low, moderate
and high levels of infection intensity), stool sampling (2 stool
samples of 2 different days both before and after administration
of drugs), the FEC method (Kato-Katz thick smear with a detection
limit of 24 epg) and thresholds deﬁning reduced efﬁcacy (ERR <70%
for A. lumbricoides and <50% for T. trichiura and hookworm). How-
ever, as discussed above these guidelines need to be revised in the
light of the information that has come to hand since then and the
data critically reviewed in this paper. Another important implica-
tion of the current guidelines is the additional amount of technical
and ﬁnancial resources that are required to undertake studies to
monitor anthelmintic efﬁcacy under these WHO guidelines. Based
on the cost assessment of the Kato-Katz thick smear for STH diag-
nosis by Speich et al. (2010), it can be deduced that such stool sam-
pling would require US$ 3.46 per subject.
In the light of evidence accrued since the publication of these
guidelines for monitoring drug efﬁcacy, agreement on the most
appropriate and valid monitoring of chemotherapy-based hel-
minth control programmes is urgently required. The approach
should be standardised and consistent throughout so that changes
in drug efﬁcacy with time can be readily identiﬁed and that the
outcomes from trials in different years and locations can be legiti-
mately compared.
For this purpose we propose the following algorithm for moni-
toring drug efﬁcacy in future trials (Fig. 1). The monitoring of trials
should be based on a target random minimal sample of 200 sub-
jects, independent of their infection status (negative/positive), le-
vel and variation in egg excretion. The number of subjects to
recruit, however, will depend largely on the proportion of the sub-
jects meeting the inclusion criteria (between 6 and 12 years,
Fig. 1. Flow chart on how to monitor and to interpret drug efﬁcacy during mass drug administration programmes. ⁄N is based on the formula below
N ¼ 200ð100%-expected proportion of subjects not meeting the inclusion criteria in %Þ  ð100%-expected dropout in %Þ N ¼
200
ð0:95Þ  ð0:95Þ ¼ 222. For example, for 5% of
the subjects not meeting the inclusion criteria and an expected dropout of 5% recruitment of 222 subjects is recommended. ⁄⁄At present, there is no inference available to
calculate 95% conﬁdence interval for the ERR formula. Bootstrap analysis, therefore is recommended. ⁄⁄⁄Baseline FEC of all subjects examined are lowly aggregated when
k > 0.01. k ¼ ðarithmetic mean of baseline FECÞ
2
Variance baseline FEC arithmetic mean of FEC.
⁄⁄⁄⁄Based on baseline FEC of infected subjects only.
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Table 1
Calculations of the cure rate (CR) and egg reduction rate (ERR) for a ﬁctitious efﬁcacy
trial against T. trichiura.
Subject FEC at baseline (EPG) FEC at follow-up (EPG ERRi (%)
Ln (x + 1) Ln (x + 1)
A 10,000 9.2 1,000 6.9 90.0
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the compliance rate at follow-up. Two stool samples per subject
should be examined (1 at baseline and 1 at follow-up). The recom-
mendation of a reduction in stool samples per subject (previously 2
at baseline and 2 at follow-up according to WHO guidelines) may
seem surprising but it is justiﬁed, because any variation in FEC
across time (some individual FEC will be overestimated) will have
no or very little impact on the ERR based on the arithmetic mean
FEC at the group level. The above approach therefore represents
a compromise between the collection of unnecessarily detailed
data with associated cost and time, and achieving what is practical
in a ﬁeld setting with expectation of good compliance from the
subjects involved.
On account of their simplicity, the McMaster egg counting
(Levecke et al., 2009) and the Kato-Katz thick smear methods
(World Health Organization, 1991) are the FEC methods of choice
in large-scale surveys. Although the Kato Katz is more sensitive
and detects higher FEC for A. lumbricodes infections (Levecke
et al., 2011a), it is not a method of choice where hookworms are
highly prevalent and the major subjects of the trial. Yet, both meth-
ods provide comparable ERR results for all STH (unpublished re-
sults, Albonico et al.). The FEC of the subjects at follow-up should
be assessed at 7–14 days after the administration of drugs. The
ERR should be calculated subsequently based on the ratio of the
arithmetic mean of FEC at follow-up and the arithmetic mean of
baseline FEC (Vercruysse et al., 2011). Subsequently, 95% conﬁ-
dence intervals should be calculated based on bootstrap analysis
(10,000 iterations).
Vercruysse et al. (2011) recommended that in future monitor-
ing of single-dose ALB-dependent control programmes a minimum
ERR (based on arithmetic means) of 95% for A. lumbricoides and 90%
for hookworms should be used as current thresholds, independent
of the baseline FEC. For T. trichiura, the thresholds depend on the
mean baseline FEC of the infected subjects, being 90%, 70% and
50% for trials where the mean baseline FEC is less than 275 EPG,
550 and 800 EPG, respectively (Levecke et al., in press). Any reduc-
tion from these proposed thresholds (upper limit of 95%
CI < threshold) should trigger the need for further investigation.
However, it is important to note, that ERR can only be interpreted
when the baseline FEC across the 200 subjects shows a low degree
of aggregation (k of negative binomial distribution >0.01, Fig. 1)
and/or the group comprises a minimum of at least 30 infected chil-
dren. Given the above, and for the sake of consistency in future
reporting, trial investigators should report the ERR in all three
FEC intensity classes for all species, as well as for the combined
dataset.
In the ﬁrst instance, programme managers and investigators
should investigate the performance of key aspects of the control
programme, including (1) coverage of the programme (the propor-
tion of target children that received drugs), (2) compliance of the
children (the proportion of children that received the tablet and
actually swallowed it) and (3) the source of and storage conditions
of the anthelmintic (allowing the presence and quantity of active
ingredient, dissolution and disintegration times to be subsequently
tested in the event of apparent low efﬁcacy). If these potential con-
founding factors can be ruled out, conﬁrmation of AR by either
in vitro biological or molecular assays is strongly recommended.B 1000 6.9 100 4.6 90.0
C 100 4.6 10 2.4 90.0
D 10 2.4 15 2.8 50.0
E 10 2.4 1 0.7 90.0
AR mean 2224.0 5.1 225.2 3.5 62.0
GEO mean 164.0 31.4
CR = 100%  (1–4/4) = 0.0%.
ERR[1] = 100%  (1–225.2/2224.0) = 89.9%.
ERR[2] = 100%  (1–31.4/164.0) = 80.9%.
ERR[3] = 62.0%.9. Conclusions, research priorities and recommendation for
SOPs
The limited number of studies in the public domain that have
reported reduced efﬁcacy of anthelmintics does not yet provide
conclusive evidence of drug resistance among human STH, but
the warning signs are clear. Moreover, research is critically neededto understand the genetic and molecular basis of anthelmintic
resistance in humans; while putative resistance alleles have been
found in human STH, so far there are no studies investigating
changes in the frequency of resistance mutations following drug
pressure (Box 2).
The few studies of AR in STH carried out so far have been con-
founded by methodological ﬂaws e.g. type of diagnostic methods,
treatment regimens, drug dose rates, geographical location. There
is a lack of adequate guidelines through which managers of control
programmes can be informed how best to react should treatment
failures occur in public health settings. Surveys for monitoring
drug efﬁcacy need to be undertaken regularly implementing stan-
dard operating procedures (SOPs) that will ensure consistency and
uniformity.
As the recommended monitoring indicator highlighted in this
review (that is, ERR) is dependent on the intensity of pre-treatment
STH infection, especially in the case of T. trichiura, we believe that
this confounding effect is best avoided by reporting ERR separately
for each intensity class, as well as overall, and we strongly
recommend that this be adopted as a SOP for all species (not just
T. trichiura) to avoid inconsistencies in reporting. A clear deﬁnition
of drug resistance with evidence-based thresholds for each STH is
one of the most pressing needs, and the values we have provided
here for different baseline FECs in the case of T. trichiura and overall
in the case of A. lumbricoides and hookworms, against which the
obtained ERR, are a useful starting point. As more data become
available, once SOPs have been implemented and become estab-
lished and universally used, it should be possible in time to reﬁne
the actual values, but for the present those given here should be
implemented in all trials (SOP). In order to generate conﬁdence
in the robustness of the ERR in each intensity class, calculations
should only be reported for intensity classes where at least 30 sub-
jects were treated (SOP). The recommendations suggested in this
review should be translated now into practical algorithms for
application in the ﬁeld and should serve as the platform of an even-
tual more comprehensive document that the Department of Ne-
glected Tropical Diseases at the WHO is requesting the WHO
collaborating centres to produce in order to address this pressing
yet neglected issue.
Given the focus of this review on identifying AR in human STH,
it is important to emphasise that should AR be detected and con-
ﬁrmed as such, there are is still no agreed strategy in the public do-
main, as to how to deal with it. This now requires urgent
consideration and agreement. It is pertinent that only a limited
number of anthelmintic classes are available for treatment of hu-
man STH. Therefore, there is an urgent need to develop new
anthelmintics that work through novel modes of action. Already
Box 1
Deﬁnition and formulae for calculating the cure rate (CR) and
egg reduction rate (ERR)
CR and ERR are the most applied metrics for assessing
anthelmintic efﬁcacy. The CR equals the percentage of subjects
who no longer pass eggs after treatment, whereas the ERR
equals the reduction in the number of eggs excreted. Formulae
for calculating these metrics are provided below. In contrast to
the CR, various formulae have been used for calculating the
ERR. These formulae differ with respect to the mean (arithme-
tic vs. geometric) and statistical unit under consideration
(group vs. subject). ERR[1] and ERR[2] provide ERR at the level
of the group, whereas ERR[3] provides ERR at the level of the
subject (= mean of individual ERR).
CR ¼ 100%
 1 number of subjects excreting eggs at follow-up
number of subjects excreting eggs at baseline
 
ERR½1 ¼ 100%
 1 arithmetic mean of group FEC at follow-up













 1 geometric mean of group FEC at follow-up
geometric mean of group FEC at baseline
 
¼ 100% 1 e
Pn










ERR½3 ¼ 100% 1 arithmetic mean of individual FEC at follow-up









An example is provided in Table 1, to illustrate inmore detail
the different metrics/formulae and their consequences. In this
example, the efﬁcacy of a drug against T. trichiurawas evaluated
in ﬁve subjects (A–E). At baseline, all subjects excreted eggs,
with the FEC ranging from 10 to 10,000 EPG (arithmetic
mean = 2224.0 EPG, geometric mean = 164.0 EPG). At follow-
up, eggs of T. trichiura were found in all subjects, with the FEC
ranging from 15 to 1,000 EPG (arithmetic mean = 225.2 EPG,
geometric mean = 31.4 EPG). The CR in the present example
was 0.0%, the ERR ranged from 62.0% to 89.9%, depending on
the ERR formula used. ERR[3] yielded the lowest ERR result,
which can be explained by the speciﬁc ERR of subject D. For this
subject, the FEC at follow-up was higher than those at baseline
resulting in a negative ERRi, which is in sharp contrast to the
remaining four subjects for whom high ERRi were observed. In
this ERR formula, however, each of the subjects included pro-
vides an equally weighted contribution to the outcome, and
hence interpretation is highly sensitive to extreme values (see
also Vercruysse et al., 2011). Group based formulas are more
robust with respect to extreme values, yet the difference
between ERR[1] and ERR[2] is still remarkable. A detailed study
explaining these differences was conducted by Dobson et al.
(2009), highlighting that ERR[2] is more prone to bias than
ERR[1].
Box 2
Research priorities to mitigate and monitor anthelmintic resis-
tance for human soil-transmitted helminths
 Standardization of methods for determining ERR,
including:
o Quantitative parasitologic technique
o Quantity of stool analysed
o Statistical methodology
 Standardizing trial design and monitoring strategy to
detect anthelmintic resistance, including:
o Population size
o Infection intensity strata
o Thresholds for deﬁning suboptimal response
 Comprehensive survey of resistance-determining alleles in
STH
o E.g., the codon 200 polymorphism in b-tubulin
o Development of ‘‘user-friendly’’ and low cost molecular
assays for detection of resistance allele
 Mathematical modelling of the effect of various factors on
the evolution of anthelmintic resistance, including:
o Dose regimen and clinical efﬁcacy
o Background resistance allele frequency
o Refugia
 Development and standardization of in vitro assays of AHR
o Assay methodology
o Thresholds for deﬁning suboptimal response
o Developing new tests to measure drug resistance phe-
notype in STH that do not hatch in the environment
(A. lumbricoides and T. trichiura)
 Using modern techniques to deﬁne the pharmacokinetics
in humans of relevant anthelmintics
 Improvements to the current armoury of anthelmintics
o Optimization of dosages, dose rates and treatment
schedules with current anthelmintics
 Assessment of combination therapies for efﬁcacy against
human STH
 Development of novel anthelmintics that are unlikely to
share resistance mechanisms with current anthelmintics
(e.g. operate through different modes of action)
 Collection of resistant lines of human STH
o For use as positive controls in in vitro assessments of
ﬁeld samples
o For investigation of the molecular and genetic basis of
AR.
24 J. Vercruysse et al. / International Journal for Parasitology: Drugs and Drug Resistance 1 (2011) 14–27in the veterinary ﬁeld a limited number of such candidates, meet-
ing some of the criteria for selection, have been developed in re-
cent years but none are ideal for treatment of STH e.g. the two
veterinary products, emodepside (currently very expensive) and
monepantel (activity against STH is currently being assessed, per-
sonal communication), and tribendimidine and nitazoxanide,
which have been approved for human use but still have limited
utility (Xiao et al., 2005; Olliaro et al., 2011). Should AR arise immi-
nently and spread, at a time when our anthelmintic armoury is still
so limited, we may have to resort to traditional methods of control
based on improvements in sanitation, education to change human
behaviour and to ensure that footwear is more widely adopted in
the case of hookworm control. The worrying aspect of this, of
course, is that we have known about the relevance of these latter
control measures for well over a century, but STH have persisted
nevertheless.
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